huTIGIT-Jurkat is primarily used as a cellular assay system in immunological research and drug development. It serves as a reporter cell line engineered to study the TIGIT pathway, an immune checkpoint involved in regulating T-cell activity. This cell line is commonly used to evaluate the function and potency of therapeutic antibodies or inhibitors targeting the TIGIT pathway. When exposed to ligands or modulators of TIGIT, the cells produce a measurable signal, such as luminescence or fluorescence, enabling high-throughput screening of candidate drugs. It is especially valuable in oncology research for developing immunotherapies that aim to enhance anti-tumor immune responses by blocking inhibitory signals. The system supports consistent, reproducible assessment of TIGIT-mediated signaling in a human-relevant cellular context.